• Oculis Holding AG OCS.OQ reported a quarterly adjusted loss of 69 rappen​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -44 rappen. The mean expectation of seven analysts for the quarter was for a loss of 44 rappen per share. Wall Street expected results to range from -51 rappen to -38 rappen per share.

• Revenue rose 28.4% to CHF285.00 thousand from a year ago; analysts expected CHF219.29 thousand.

• Oculis Holding AG's reported EPS for the quarter was a loss of 69 rappen​.

• The company reported a quarterly loss of CHF33.21 million.

• Oculis Holding AG shares had fallen by 3.2% this quarter and gained 8.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 12.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

• Wall Street's median 12-month price target for Oculis Holding AG is $32.00

This summary was machine generated from LSEG data May 9 at 12:25 a.m. UTC. ​All figures in Swiss francs unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)